Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior nonsteroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2016, 2016, roč. 11, č. 4, s. 250-251.